Capricor Therapeutics modified its statistical analysis plan without obtaining prior approval from the FDA.
2 reports, 1 independent
Updated Sep 15
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Capricor Therapeutics modified its statistical analysis plan without obtaining prior approval from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA requested additional clinical data from Unicycive Therapeutics.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
- The FDA has questioned promotional materials related to an investigational drug from Alar Pharmaceuticals.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.